Formosa Pharmaceuticals, Inc. Stock

Formosa Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the development of early drug candiate and pre-clinical drug products. The Company also conducts the research and development of nanotechnology platform and dosage form design, and uses the patented nano platform to overcome the challenges of low dissociation rate and poor bioavailability in the development of pharmaceutical dosage forms. In the research and development projects, the ophthalmic drug APP13007 has entered the phase III clinical trial stage, and its indications are anti-ocular postoperative inflammation, and its main appeal is to reduce postoperative inflammation and pain. TSY-0110 has entered the preclinical stage to develop antibody-drug conjugate (ADC) to cure breast cancer. The innovative small molecule compound MPT0E028 has completed the first phase of clinical trials and is expected to be used in the field of anti-cancer therapy.